Next Article in Journal
Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer
Previous Article in Journal
Perspectives on Treatment Advances for Stage III Locally Advanced Unresectable Non-Small-Cell Lung Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 1
10.3747/co.26.4220
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer

by
Susan Dent
1,*,
C. Ammendolea
2,
A. Christofides
3,
S. Edwards
4,
D. Incekol
5,
B. Pourmirza
6,
S. Kfoury
6 and
B. Poirier
7
1
Duke Cancer Center, 20 Duke Medicine Circle, Durham, NC 27710, USA
2
Canadian Breast Cancer Network, Montreal, QC, Canada
3
impact Medicom Inc., Toronto, ON, Canada
4
Dr. H. Bliss Murphy Cancer Centre, Memorial University, St. John’s, NL, Canada
5
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
6
Hoffmann–La Roche, Mississauga, ON, Canada
7
Centre des maladies du sein, Hôpital du Saint-Sacrement, CHU de Québec–Université Laval, Québec, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(1), 70-80; https://doi.org/10.3747/co.26.4220
Submission received: 3 November 2018 / Revised: 5 December 2018 / Accepted: 10 January 2019 / Published: 1 February 2019

Abstract

Trastuzumab is the standard treatment in Canada for patients with breast cancer positive for HER2 (human epidermal growth factor receptor 2), dramatically improving outcomes in that patient group. However, its current intravenous (IV) administration is associated with long infusion times that place a significant burden on health care resources and patient quality of life. In an effort to provide a faster and easier administration method, a subcutaneous (SC) formulation of trastuzumab has been developed. Data from comparative trials demonstrate that the two formulations are comparable with respect to pharmacokinetics and efficacy. They also have similar safety profiles, with the exception of mild local and administration reactions with the SC formulation. Furthermore, the SC formulation is preferred by patients and health care professionals, and greatly reduces administration and chair time. Additional advantages include easier preparation and dosing, reduced drug wastage, and reduced discomfort at the injection site. By using well-thought-out administration procedures, the SC formulation can be given safely and effectively, potentially reducing the burden on health care resources and improving quality of life for patients.
Keywords: trastuzumab; subcutaneous administration; breast cancer; her2 positivity trastuzumab; subcutaneous administration; breast cancer; her2 positivity

Share and Cite

MDPI and ACS Style

Dent, S.; Ammendolea, C.; Christofides, A.; Edwards, S.; Incekol, D.; Pourmirza, B.; Kfoury, S.; Poirier, B. A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer. Curr. Oncol. 2019, 26, 70-80. https://doi.org/10.3747/co.26.4220

AMA Style

Dent S, Ammendolea C, Christofides A, Edwards S, Incekol D, Pourmirza B, Kfoury S, Poirier B. A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer. Current Oncology. 2019; 26(1):70-80. https://doi.org/10.3747/co.26.4220

Chicago/Turabian Style

Dent, Susan, C. Ammendolea, A. Christofides, S. Edwards, D. Incekol, B. Pourmirza, S. Kfoury, and B. Poirier. 2019. "A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer" Current Oncology 26, no. 1: 70-80. https://doi.org/10.3747/co.26.4220

APA Style

Dent, S., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., Kfoury, S., & Poirier, B. (2019). A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer. Current Oncology, 26(1), 70-80. https://doi.org/10.3747/co.26.4220

Article Metrics

Back to TopTop